Aurora Cannabis (TSE:ACB) Given a C$10.00 Price Target at Canaccord Genuity Group

Aurora Cannabis (TSE:ACB) has been given a C$10.00 price target by equities research analysts at Canaccord Genuity Group in a research report issued on Tuesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 65.56% from the stock’s current price.

Separately, ATB Capital decreased their target price on Aurora Cannabis from C$9.00 to C$8.50 and set an “outperform” rating for the company in a research report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of C$9.25.

Aurora Cannabis Trading Up 1.7%

Shares of TSE:ACB traded up C$0.10 during midday trading on Tuesday, hitting C$6.04. 237,421 shares of the stock traded hands, compared to its average volume of 475,242. The company has a quick ratio of 2.48, a current ratio of 3.42 and a debt-to-equity ratio of 18.72. The business’s 50 day moving average is C$6.24 and its two-hundred day moving average is C$6.69. The stock has a market capitalization of C$339.73 million, a PE ratio of -5.92 and a beta of 0.71. Aurora Cannabis has a one year low of C$4.95 and a one year high of C$9.90.

Aurora Cannabis (TSE:ACB) last issued its quarterly earnings data on Wednesday, November 5th. The company reported C($0.91) EPS for the quarter. The company had revenue of C$90.37 million during the quarter. Aurora Cannabis had a negative return on equity of 8.36% and a negative net margin of 22.55%. As a group, research analysts forecast that Aurora Cannabis will post -0.22 earnings per share for the current year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.